@article{33323a5b609a473b83614f55c5bc074e,
title = "Suppression of extrapyramidal side effects of doxepin by thalamic deep brain stimulation for tourettesyndrome",
author = "L. Rzesnitzek and T. W{\"a}chter and R. Kr{\"u}ger and A. Gharabaghi and C. Plewnia",
note = "Funding Information: Disclosure: Dr. Rzesnitzek reports no disclosures. Dr. W{\"a}chter has received funding for travel and/or speaker honoraria from Medtronic, Inc., Solvay Pharmaceuticals, Inc./Abbott, and SCHWARZ PHARMA and holds stock/stock options in Gilead Sciences, Inc. Dr. Gharabaghi receives research support from the German Research Council (DFG), the German Ministry for Education and Research (BMBF), Medtronic, Inc., and the European Union. Dr. Kr{\"u}ger has received funding for travel and/or speaker honoraria from UCB, Cephalon, Inc., Abbott, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Medtronic, Inc.; serves as an Associate Editor for the European Journal of Clinical Investigations, the Journal of Neural Transmission, and BMC Neurology; and receives research support from the German Research Council (DFG), and the Federal Ministry for Education and Research (BMBF). Dr. Plewnia has received speaker honoraria from inomed Medizintechnik GmbH and Deutsche Tinnitus Liga and receives research support from inomed Medizintechnik GmbH, Northstar Neuroscience, and the German Research Council (DFG). Funding Information: Study funding: This collaborative work of the T{\"u}bingen Brain Stimulation Network (T{\"u}bingen BrainStimNet) was supported by a grant from the University of T{\"u}bingen (AKF 238–0-0) . ",
year = "2011",
month = nov,
day = "1",
doi = "10.1212/WNL.0b013e318236485f",
language = "English",
volume = "77",
pages = "1708--1709",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "18",
}